Carlyle and Warburg Pincus led a $123m series D round in Abbisko Therapeutics.

Private equity firms The Carlyle Group and Warburg Pincus led a $123m series D funding round in Abbisko Therapeutics, a biopharmaceutical and drug development company. OrbiMed, Lake Bleu Capital, Janchor Partners, Sage Partners, Greater Bay Area Homeland, Lilly Asia Ventures, Temasek Holdings, Qiming Venture Partners, Hankang Capital and CICC Capital also joined the round. The proceeds will be used to accelerate the progress of its clinical programs and further expand its preclinical pipeline.